Abstract:AIM: To evaluate the efficacy and reliability of Ziprasidone injection made in China in treating acute onset of schizophrenia.METHODS: Sixty inpatients with schizophrenia, who were hospitalized in the Mental Health Institute, Second Xiangya Hospital of Central South University between March 2003 and May 2004, were randomly divided into Ziprasidone group (n=30) and Haloperidol group (n=30) in a single-blinded, double modeling study. All the patients were treated with intramuscular injection Ziprasidone (10-20 mg) or Haloperidol(5-10 mg) at once when they were hospitalized. The range of dosage for Ziprasidone was no more than 40 mg per day and that of Haloperidol was no more than 30 mg per day. The treatment duration was three days. Before treatment and at 2, 6, 24, 48 and 72 hours after treatment respectively, the efficacy was evaluated with the decreasing rate of excitement factor score and change of total score of positive and negative syndrome scale (PANSS), decreasing rate of score (%)=(score before treatment -score after treatment)/ score before treatment×100%. The efficacy was divided into 4 grades, decreasing rate of score ≥ 80% as clinical full recovery, ≥ 50% as significant effect, ≥ 30% as turned better, < 30% as invalid. The occurrence of side effects was assessed with treatment emergent symptom scale (TESS) and rating scale for extrapyramidal side effects (SAS) were employed to evaluate the efficacy and side-effect. The t test, rank sum test and analysis of variance (ANOVA) were applied in the intergroup comparison of measurement data, and the χ2 test was used in the comparison of enumeration data. RESULTS: All the 60 patients were involved in the analysis of results, and no one lost to the process of treatment and follow-up. ① The decreasing rate of excitement factor score and change of total score of PANSS: At 72 hours after treatment, the total score of excitement factor of PANSS in the Ziprasidone group was significantly reduced as compared with that before treatment, the decreasing rate of score was (47.33 ±26.07)%, and the total clinical effective rate was 47.33%. The total score of excitement factor of PANSS in the Haloperidol group was also significantly reduced as compared with that before treatment, the decreasing rate of score was (48.53±21.99)%, and the total clinical effective rate was 48.53%. There were no significant differences between the two groups (P > 0.05). ② Occurrence of side effects: The Fisher test showed that the incidence rate of side effects had no significant difference between the Ziprasidone group and Haloperidol group (37%, 50%, P > 0.05). The statistical analysis of rating scale for extrapyramidal side effects indicated that the incidence rates of polysialia and extrapyramidal symptoms in the Ziprasidone group were obviously lower than those in the Haloperidol group (P < 0.05).CONCLUSION: Ziprasidone made in China has distinct efficacy in treating the acute onset of schizophrenia as Haloperidol without obvious side effects, and the side effects are fewer than Haloperidol.

Cost Effectiveness Analysis of Blonanserin Versus Ziprasidone As First-Line Treatment for Patients with Schizophrenia in China

Improvement of Social Functioning in Patients with First-Episode Schizophrenia Using Blonanserin Treatment: a Prospective, Multi-Centre, Single-Arm Clinical Trial

Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial

Cost-utility Analysis of Lurasidone for the First-Line Treatment of Schizophrenia in China

Cost-Effectiveness Analysis of Amisulpride and Olanzapine for Patients with Schizophrenia in China

Cost-effectiveness of Olanzapine in the First-Line Treatment of Schizophrenia in China.

Cost-effectiveness analysis of five clinical commonly used atypical antipsychotics as the first-line treatment of first-episode schizophrenia in China based on a decision tree model

Cost-effectiveness of Long-Acting Risperidone Injection Versus Alternative Atypical Antipsychotic Agents in Patients with Schizophrenia in China.

Comparative Cost-Effectiveness of Amisulpride and Olanzapine in the Treatment of Schizophrenia in China.

Comparative Efficacy and Safety Between Amisulpride and Olanzapine in Schizophrenia Treatment and a Cost Analysis in China: a Systematic Review, Meta-Analysis, and Cost-Minimization Analysis.

Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial

Safety and Effectiveness of Oral Blonanserin for Schizophrenia in Adolescents in China: Data from a 12-Week Post-Marketing Surveillance

Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: an Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance.

Cost-effectiveness Analysis of Psychosocial Intervention for Early Stage Schizophrenia in China: a Randomized, One-Year Study

Effectiveness and Safety of Blonanserin in Young and Middle-Aged Female Patients with Schizophrenia: Data from a Post-Marketing Surveillance

Literature review and economic evaluation of oral and intramuscular ziprasidone treatment among patients with schizophrenia in China

Model‐based Analysis of Therapeutic Efficacy of Blonanserin and Risperidone in Schizophrenia Patients and Effects on Prolactin: A Randomized Double‐blind Study

Double-blind Comparison of Ziprasidone and Risperidone in the Treatment of Chinese Patients with Acute Exacerbation of Schizophrenia

Who Can Benefit More from Its Twelve-Week Treatment: A Prospective Cohort Study of Blonanserin for Patients with Schizophrenia

Ziprasidone made in China and Haloperidol in treating acute onset of schizophrenia: A randomized, single blinded, double modelling, parallel control study

Bioequivalence of Blonanserin Tablets under Fasting and Fed Conditions in Healthy Chinese Subjects.